Quick answers
- What is Perindopril erbumine used for?
- The FDA-approved label (Perindopril Erbumine, Aurobindo Pharma Limited, March 13, 2024) says: “Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. 1.1 Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Perindopril erbumine have a boxed warning?
- Yes. The FDA label for Perindopril Erbumine has a boxed warning (“WARNING: FETAL TOXICITY”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Perindopril erbumine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Perindopril erbumine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Perindopril erbumine?
- 1 company lists prescription products of Perindopril erbumine in the FDA NDC Directory, including Aurobindo Pharma Limited.
What Perindopril erbumine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. 1.1 Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. …
— FDA label: Perindopril Erbumine, Aurobindo Pharma Limited, effective March 13, 2024. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: FETAL TOXICITY
. Read it on the full label →
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 3 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| perindopril erbumine 2 mg tablet | Generic | $0.4884 per tablet |
| perindopril erbumine 4 mg tablet | Generic | $0.4920 per tablet |
| perindopril erbumine 8 mg tablet | Generic | $0.5420 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Aurobindo Pharma Limited3 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (1)
- ANDA079070Aurobindo Pharma · November 10, 2009
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 854925, 854984, 854988 |
|---|---|
| SPL set ID of the quoted label | 87768fbf-7c63-47da-8925-0316f343d6ef |
| FDA labels (SPL) | 1 |
| FDA applications | 1 ANDA |
| Active ingredients (FDA) | PERINDOPRIL ERBUMINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Perindopril Erbumine, Aurobindo Pharma Limited, effective March 13, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →